Neuspera Medical Secures $23 Million to Advance Minimally Invasive Treatment for Overactive Bladder
Neuspera Medical, a company pioneering a discreet and minimally invasive treatment for overactive bladder (OAB), has secured $23 million in Series D financing. This significant investment round, led by Vertex Ventures HC and Treo Ventures, will propel Neuspera’s Neuspera System through U.S. Food and Drug Administration (FDA) premarket approval (PMA) and towards commercialization. OAB, a…